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ABSTRACT
Objective: To understand the perspectives of women
with severe mental illness concerning the use of
psychotropic medicines while pregnant.
Design: Interviews conducted by female peer
researchers with personal experience of making or
considering decisions about using psychotropic
medicines in pregnancy, supported by professional
researchers.
Participants: 12 women who had had a baby in the
past 5 years and had taken antipsychotics or mood-
stabilisers for severe mental illness within the 12-
month period immediately prior to that pregnancy.
Recruitment to the study was via peer networks and
the women interviewed came from different regions of
England.
Setting: Interviews were arranged in places where
women felt comfortable and that accommodated their
childcare needs including their home, local library and
the research office.
Results: The views expressed demonstrated complex
attempts to engage with decision-making about the use
of psychotropic medicines in pregnancy. In nearly all
cases, the women expressed the view that healthcare
professionals had access to limited information leaving
women to rely on experiential and common sense
evidence when making decisions about medicine
taking during pregnancy.
Conclusions: The findings complement existing work
using electronic health records by providing
explanations for the discontinuation of psychotropic
medicines in pregnancy. Further work is necessary to
understand health professionals’ perspectives on the
provision of services and care to women with severe
mental illness during pregnancy.
INTRODUCTION
Many women with severe mental illness
treated with psychotropic medication
become pregnant.1–3 However, no psycho-
tropic medication has UK marketing author-
isation speciﬁcally for pregnant women or
for use when breast feeding.4 5 This leaves
women and their healthcare professionals in
a treatment dilemma in relation to the use
or otherwise of psychotropic medicine in
pregnancy, with the need to balance the
health of the women with that of the unborn
child without recourse to an established evi-
dence base.6–9 Advice on treatment varies
across countries and in some instances stand-
ard psychiatric advice is that women main-
tain pharmacological treatment across the
perinatal period.10 The 2014 National
Institute for Health and Care Excellence
(NICE) guidelines for antenatal and post-
natal mental health provide some guidelines
for speciﬁc treatments, such as lithium and
valproate, but the evidence base for other
treatments is limited.4 The higher threshold
for starting any treatment in pregnancy is,
however, noted.4
Analysis of data from established electronic
health records such as The Health
Improvement Network (THIN) and the
Clinical Practice Research Datalink (CPRD)
primary care databases, as well as US insur-
ance claims databases, shows pregnancy to
Strengths and limitations of this study
▪ Women with personal experience of using anti-
psychotic medications and making or consider-
ing decisions about medicines and pregnancy,
supported by professional researchers, devel-
oped the research questions, designed the study
and conducted the interviews.
▪ Women with personal experiences of decisions
about the use of antipsychotic medications were
involved in the analysis; grounding the findings
in patient experience.
▪ The findings are based on what the women
recalled about their decision-making at that time.
▪ Further work is needed to consider women’s
accounts while pregnant, the perspectives of
healthcare professionals, fathers and other family
members.
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be a key determinant for stopping most psychotropic
medications.11–17 Petersen et al14 showed that this was
the case for antidepressants; with the decline in prescrib-
ing the most profound in the ﬁrst 6 weeks of pregnancy.
A similar pattern was observed for antiepileptic drugs,
with pregnancy a determinant for discontinuation, par-
ticularly for women with bipolar disorder or depres-
sion.12 Focusing on antipsychotics, <40% of women who
received atypical antipsychotics prior to pregnancy were
still in receipt of them at the start of their third trimes-
ter. For typical antipsychotics, the ﬁgure was down to
19% by the start of the third trimester,11 and for lithium
the ﬁgure was 29%.18 It has, however, been argued that
although reductions in prescribing of psychotropic med-
icines in pregnancy might be explained by concerns
about adverse effects of the drugs, this needs to be
balanced against the potential harm of inadequate treat-
ment during pregnancy.9 12 14 19–21 From the perspective
of women, analysis of a Norwegian questionnaire study
involving pregnant women, or those with a child under
the age of ﬁve, found that the harmful effect of all
drugs in pregnancy was overestimated, with the risks of
antidepressants perceived to be on a par with alcohol,
smoking and thalidomide.22 Similar ﬁndings have been
reported in studies based in Europe, North America and
Australia.23
Overall, little is known about the real-world decision-
making processes navigated by women and their health-
care providers around whether to initiate and/or con-
tinue psychopharmacology during pregnancy and about
how women weigh and consider information, personal
beliefs, life experiences and perceptions of their mental
health needs and treatment preferences to make deci-
sions about their use of psychiatric medication.24 The
recently updated NICE guidelines4 state that the pre-
scriber should take into account individual needs and
preferences and that women should have the opportun-
ity to make informed decisions about their care and
treatment, in partnership with healthcare professionals.
Discussions should involve the potential beneﬁts of psy-
chological interventions and psychotropic medication,
the possible consequences of no treatment, the possible
harms associated with treatment and what might happen
if treatment is changed or stopped, particularly if psy-
chotropic medication is stopped abruptly.4 Moreover,
the complexity, and associated uncertainty, of making
decisions about medicine taking during pregnancy for
women with mental health problems is explicitly
acknowledged in relation to judging where changes in
mental health state and functioning (such as appetite)
may represent normal pregnancy changes or alterna-
tively may be a symptom of a mental health problem.4
All of this ﬁts with the need to work with women rather
than merely applying a model of risk management, with
the importance of such an approach also noted from
the perspective of service users.25
The research presented here provides women’s
accounts of decisions concerning the use of
psychotropic medicines while pregnant, complementing
and extending ﬁndings from studies that used electronic
health records and questionnaire surveys. It is vital to
understand the perspectives of women involved in such
decisions as they are the ones that live with the conse-
quences of decisions about medicine taking in preg-
nancy both during and after pregnancy.
METHODS
Four women with personal experience of using anti-
psychotic medications and making or considering deci-
sions about medicines and pregnancy were recruited as
peer researchers. They were supported by professional
researchers to develop research questions and design
the study. Research methods training was provided to
the four peer researchers. Twelve women who had had a
baby in the past 5 years and had taken antipsychotics or
mood-stabilisers for severe mental illness within the
12-month period immediately prior to that pregnancy
were interviewed. Interviews were conducted in pairs;
one person led the interview while the other took
charge of the recording equipment and other practical
issues. Interviews generally lasted for about 50 min, with
the shortest being 24 min and the longest 2 h 20 min.
Recruitment to the study was via peer networks and the
women interviewed came from different regions of
England. The analysis and write-up stages were led by
professional researchers with peer involvement.
The interviews explored women’s accounts of preg-
nancy and decisions about medicine taking. Women’s
mental health at the time of the pregnancy, the formal
and informal support received, use of medicines at that
time, their history of medicine taking and views and
beliefs about medicines were also explored. Women
were asked speciﬁcally about any changes made to medi-
cines when they were pregnant, how those decisions
were reached and if there was anything that might have
made decisions easier at this time. The topics covered
were developed by the peer researchers, with guidance
from the professional researchers. Interviewees raised
the issue of decisions about infant feeding in early inter-
views and this was subsequently incorporated into the
topic guide.
Interviews were arranged in places where women felt
comfortable being interviewed and that accommodated
their childcare needs. They were conducted in women’s
own homes, a local library, rented ofﬁce space and the
charity’s research ofﬁce. All interviews started by asking
women to reﬂect on what was going on in their lives
when they ﬁrst found out they were pregnant, with our
speciﬁc areas of interest introduced as prompts as the
interview developed. This was a pilot study with sufﬁ-
cient resources to conduct 12 interviews. All interviews
were fully transcribed and subject to thematic analysis.
Each of the peer and professional researchers examined
three transcripts in detail and developed their own
coding framework. These were examined in a half-day
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data clinic in which all the team members (professional
and peer researchers) presented their individual ana-
lyses. A joint coding framework was then agreed on and
applied to the data. For the purposes of this paper, an
additional analysis focusing on women’s accounts of
involvement in decision-making about medicine taking
in pregnancy, speciﬁcally in relation to accounts of the
evidence, formal and informal, used to support deci-
sions, was led by a professional researcher, with com-
ments from the rest of the team.
FINDINGS
Key characteristics of the sample are provided in table 1.
The accounts provided by the women in the study are
considered in relation to information-seeking behaviour,
the use of experiential evidence and the effects of access
to services on women’s medicine taking.
Information seeking
As can be seen in table 1, six women reported that their
pregnancies were planned, ﬁve as unplanned, and in
one interview it was unclear. Of those who reported that
their pregnancies were planned, ﬁve of the six reported
discussing this with a medical practitioner prior to the
pregnancy. One woman reported having discussed the
possibility of getting pregnant with her doctor at some
period in the past, but her pregnancy was unplanned.
Another woman reported having done a lot of research
but did not discuss the role of the medical profession as
part of that research; a possible explanation for this was
that she was not using any services at the time. In
summary, the women in our sample reported actively
seeking advice prior to a planned pregnancy and in
general were aware of their mental health needs and
keen to be involved with decisions that affected their
health.
It was, however, generally agreed that there was a lack
of evidence available in relation to the risks and beneﬁts
of taking psychotropic medicines in pregnancy.
Consequently, even where women reported feeling sup-
ported, decisions were described as taking a ‘punt’ or
‘gamble’.
You have to make the decision based on no information
really (P05)
Yet for women making decisions, the stakes in relation
to their own health and that of their unborn child are
very high. Although some women did discuss the role of
their partner and wider friends and family in providing
support, only two presented and discussed their deci-
sions in such a way as to indicate joint decisions.
Criticism was directed at doctors who provided deﬁni-
tive answers, not just because of the dearth of evidence
but particularly where this did not allow for discussion
of the basis for advice and associated uncertainty. This
was presented as particularly problematic as it assumes
women and medical professionals judge risks and bene-
ﬁts and the inevitable trade-offs in the same way.
I think clinicians can sometimes feel the need to give
what sounds like a deﬁnitive answer, even if there isn’t
one, and actually it would be better to say there isn’t
enough research yet (P08)
In contrast, failure to provide a strong direction could
mean people felt they had to ‘resort’ to seeking guid-
ance from the internet.
If she’d have said I’d rather you didn’t take it then I
would have stopped it, but she was just very wishy
washy…So I then went and you know had a look on the
internet to see what was going on (P07)
Most of the women in our study indicated that they
had used the internet to search for information about
the use and effects of psychotropic drugs in pregnancy.
The internet was used to search for research papers,
information about the effects on child development of
mothers taking psychotropic medicines in pregnancy,
and information about different formulations of psycho-
tropic medicines. Some women presented accounts
about use of the internet in general suggesting that they
probably had used it when considering the use of psy-
chotropic medicines in pregnancy based on the fact they
that had used it for information about medication in the
past. This lack of speciﬁc detail may be indicative of the
Table 1 Key characteristics of women interviewed (n=11)*
Characteristics Count
Age Range 28–46 years
Mean 37.45
Ethnicity White British 8
White other 2
Arab 1
Place of residence London 7
North West 1
Yorkshire and North East 2
Eastern 2
Number of children Range 0–3
Mean 1.6
Diagnosis Schizophrenia/schizoaffective 3
Bipolar 8
Current service
support for mental
health
General practitioner 3
Secondary care services 6
Data not supplied 2
Psychotropic
medication use during
pregnancy
Took no psychotropic
medication
2
Medication in trimester one 9
Medication in trimester two 8†
Medication in trimester three 7†
Planning of pregnancy Planned 6
Unplanned 5
Unclear 1
*One participant declined to complete a participant profile form.
†In addition, one woman took antidepressants.
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normalisation of internet use for many in society.
Information from the internet was, however, criticised
for being too vague and for being inconsistent. The con-
trast between information presented in National Health
Service (NHS) guidelines and what was generally avail-
able online was noted; in particular that guidelines
present information as cut and dried, while the
internet allows access to a range of views, opinions and
experiences. Some women were appreciative of the fact
that the internet gave them access to a range of informa-
tion and evidence, despite the fact that it may be
contradictory.
With the NHS, there are the guidelines and it’s very cut
and dry isn’t it? And they will say to you, well you can
take it but the risk has got to outweigh the beneﬁts, blah
di blah blah, and that’s all you ever hear. So there’s lots
of these sites where someone will post a question and
then an American psychiatrist will answer it and they’ll
sort of give more their opinion or you know things that
they’ve seen…And some people said…my baby’s ﬁne, my
pregnancy was ﬁne, no problems whatsoever. And then
others are saying things like, oh my baby’s behind or he’s
got autism, my baby was born with disabilities (P07)
Print media was also discussed as a source of informa-
tion. One woman indicated that negative reports rein-
forced her decision not to take medicines, while for
another absence of reports was taken as indicative of the
fact that a particular medicine cannot be too dangerous.
Finally, in another example, the arguments presented in
a book were expressed as helpful by one woman in enab-
ling her to live with her decision to take medicines
throughout her pregnancy.
Experiential evidence
Experiential evidence may be central to women’s deci-
sions. This evidence may take the form of women’s own
experiences, or women may draw on the lived experi-
ences of others through, for example, the internet.
The need to control symptoms, based on experiences
when not taking medicines, was presented as the ration-
ale for some women to stay on medicines while pregnant.
And how did you feel at that point about drugs in preg-
nancy, did you have any kind of preconceptions or…?
No, I mean having had the experience that I’d had and
trying to do it without medication and ﬁnding that it
didn’t work, for me, then I sort of felt like it was import-
ant for me to stay on a stabilising dose of
Prochlorperazine and that…that if that kept me stable,
that was less of a risk to me and the baby and all that kind
of thing. So I didn’t know much about, there may be all
sorts of medical things that I’m ignorant of, in terms of
you know the effect on the foetus or whether or not it’s
best to be off them altogether. But I just felt for me, prac-
tically, I wasn’t going to get through the pregnancy
without having some kind of stabilising inﬂuence (P09)
Other women drew on previous experiences of preg-
nancy. Experiences were presented as supporting deci-
sions to take and not to take medicines. In the most
extreme case in our sample, medical guidelines were
reported to have been used to override experiential evi-
dence when a doctor reportedly would not allow a nurse
to give a pregnant woman a routine depot injection
despite the woman in question having received these
injections throughout her previous pregnancy.
I was like no, because I have a child who is four years old
and I know from my experience that I can’t come off my
medication, I know that because I’ve had one child,
throughout my whole pregnancy I’ve been on my depot
and I know how it works because my old doctor, I’ve
been with him, so he’s known me since I was like 14, I
was on the same medication throughout the pregnancy,
and I know not to come off it (P10)
She reported becoming so ill following the withdrawal
of treatment that she had an abortion. She went on to
describe how she subsequently moved into the area
covered by her previous mental health team. Her treat-
ment was then changed from depot injections to tablets
and following this change she went on to have a baby.
She presented her experience with her ﬁrst child as evi-
dence that she could continue taking medicine through-
out pregnancy without it necessarily having an adverse
effect.
Similarly, another woman reported that by the time of
her second pregnancy she had come to terms with the
necessity of taking medicines throughout pregnancy in
order to ‘stay well’. The ‘moral challenge’ potentially
presented by the use of medicines in pregnancy was dir-
ectly countered by the appeal to medicines allowing her
to stay well and ‘be a good mum’.
Did how you felt about your meds change when you
found you were pregnant or…?
No, because I think this time round and the whole sort
of process that I’d gone through to that point…my views
of the illness had changed by that time and my thinking,
which is the same as now really, is that it’s much more of
a chemical problem…that is something beyond what I
can kind of mentally sort of overcome myself, that there’s
actually some sort of fundamental chemical problem that
nothing other than the meds seems to be able to sort
out. I’ve had all kinds of talking therapies and so on and
so on and really haven’t made a difference. But…And I
ﬁnd it hard to sort of believe that taking a couple of little
tablets makes such a huge difference to the way that I
function, but…My thinking now is I clearly need them
and I want to just stay well and be a good mum (P02)
In contrast, a different woman who had previously had
a stillborn baby presented the protection of her unborn
baby from the potential effects of medication as key.
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One of the main decisions what inﬂuenced me not going
back on medication was because I wasn’t going to take
anything that risked D in the…in my womb. I’d already
lost one child…I wasn’t going to risk losing another. So
for me, I didn’t trust medi…in medication, and I had to
trust in myself (P04)
She also described a side effect of her antipsychotic
medicines to be a muting of her emotional reactions,
expressing her desire to know what it felt like to hold
her child and emotionally bond as an additional reason
to avoid taking medicines while pregnant and immedi-
ately after.
Finally, in the absence of other information, formal,
informal or experiential, women reported making deci-
sions based on the age and dose of medicines and the
common sense idea that a lower dose of an established
medicine was likely to be a lower risk than a newer medi-
cine about which little was known.
Impacts of access to services
Discussion of decisions about psychotropic medicine in
pregnancy cannot be divorced from the context and cir-
cumstances in which services are provided. For example,
one woman described working with her psychiatrist to
stop taking medicines so she could become pregnant,
but when she succeeded in stopping taking the medi-
cine she was discharged from the service with the result
that she had no support from her psychiatrist through
her pregnancy. In another case, the account was of aban-
donment and gradual deterioration, with treatment not
offered when health deteriorated.
Now in the ﬁrst trimester, I felt it was important to safe-
guard, to prevent the baby from having any of the side
effects, damage from the medication, while it’s forming.
But by the third trimester or the second trimester even,
my CPN [community psychiatric nurse] had recognised I
was showing, displaying signs of psychosis…nothing was
done (P12)
A particular problem related to the time it took for
referrals; leading to reports of medicine being either
reduced or stopped without support or of women taking
medicine by default through the ﬁrst trimester of
pregnancy.
Reports of relationships with medical professionals
were mixed. Some women described collaborative
working, while others reported being made to feel guilty
for wanting to continue or to stop medicines. As an
example, one woman described the focus placed by
health professionals on the risk of relapse and attending
classes to support parenting.
I found that because I were choosing to stay off medica-
tion, I were constantly being told, you’re 50 percent
chance likely to relapse. And I found that because I
didn’t go on meds, they made me do God knows how
many different positive parenting classes to prove that I
could be a mum (P04)
The organisation of healthcare can also have pro-
found consequences for pregnant women with long-
term mental health problems. Thus, experiences were
related of being on maternity wards on which there was
no understanding of mental health issues and of being
on a psychiatric ward where pregnancy was not sup-
ported. These experiences obviously have consequences
for the provision of care.
DISCUSSION
Medicine taking in pregnancy is perceived as risky,22 23
yet little is known about the real-world decision-making
processes navigated by women and their healthcare pro-
viders around whether to initiate and/or continue psy-
chotropic medicines during pregnancy and about how
women weigh and consider information, personal
beliefs, life experiences and perceptions of their mental
health needs and treatment preferences to make deci-
sions about their use of psychiatric medication.24 This
paper presents women’s accounts of decisions about
medicine taking and the complexity of balancing the
risks to their own mental health against possible risks to
their unborn child. In nearly all cases, the women
expressed the view that healthcare professionals
struggled to ﬁnd deﬁnitive evidence on which to base
their recommendations, leading in some cases to inter-
actional difﬁculties in the healthcare professional—
patient relationship at a crucial time in their lives.
Women were left to draw on experiential and common
sense evidence and then to ‘take a punt’ on decisions
about getting pregnant and the use of psychotropic
medicines in pregnancy. The overriding discourse was
about the complexity of women’s situations in relation
to their health and requirement of psychotropic medica-
tion to stabilise their symptoms, potential consequences
for their unborn child, and the level of support, or
otherwise, both formally and informally available.
Strengths and weakness
This paper outlines the real-world decision-making pro-
cesses navigated by women making decisions about the
use of psychotropic medication in pregnancy, which has
been identiﬁed as a gap in the literature.24 It provides
accounts of the extent to which women felt able to
make an informed choice. It does, however, draw on a
small number of participants (12 in total) and the inter-
views provide a retrospective account of their decisions
in pregnancy; therefore, the accounts provided may
have been affected by subsequent events, in particular
the health of their baby and themselves. Moreover, we
have no information from women who, having consid-
ered the potential consequences for their health of
pregnancy, have decided not to have children.
Future work
Complexity and uncertainty were recurrent themes in
women’s accounts of their interactions with healthcare
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professionals, suggesting the need for further work to
consider the perspectives of a range of healthcare pro-
fessionals and how they feel about advising women
about the use of psychotropic medicines in pregnancy.
Further work is also needed to consider women’s
accounts while pregnant and also the perspectives of
fathers and other family members. This would comple-
ment work using prescribing databases to track changes
in prescribing patterns related to pregnancy. Our ﬁnd-
ings also highlight the need for more detailed research
on the information available on the internet in relation
to the use of psychotropic drugs and use of the internet
for this purpose.
CONCLUSIONS
The ﬁndings reported here provide women’s perspec-
tives on real-world decisions made about the use of psy-
chotropic drugs in pregnancy. They provide an
understanding of the complexity of decision-making in
such circumstances and challenges inherent in making
informed decisions, given the lack of research-based evi-
dence on the effects of taking psychotropic drugs in
pregnancy. The ﬁndings complement existing work
using prescribing databases by providing explanations
for the discontinuation of psychotropic medicines in
pregnancy and identify the need for further work in
order to support health professionals in the provision of
services and care to women with long-term mental
health problems during pregnancy.
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